Media.Player

STRONG AGONIST INSULIN MIMETOPE USED IN VACCINATION TO PREVENT TYPE 1 DIABETES DEVELOPMENT

Technology Benefits

Type I Diabetes

Technology Application

Vaccination with strongly agonistic insulin mimetopes in combination with drug(s) that potentiate Tregs conversion to prevent development of type 1 diabetes in humans at risk for the disease.

Detailed Technology Description

Autoimmune T-cells with low affinity to insulin epitopes are considered to be a cause of type 1 diabetes development. The attempts to stop autoimmune attack by converting naive T cells to regulatory T cells (Tregs) using natural insulin peptides have failed in clinical trials. The DFCI scientists developed strategy to use specifically modified insulin mimetopes that are stronger agonists than natural ligand to efficiently induce Tregs and prevent diabetes development in NOD mouse model of the disease.

Supplementary Information

Inventor: von Boehmer, Harald | Daniel, Carolin
Priority Number: US20110311536A1
IPC Current: A61K0039395 | A61K003900 | A61K003902 | A61K0039235 | A61P003704 | A61P003708 | C07K000706 | C07K001900
US Class: 4241341 | 4241841 | 4241981 | 4242331 | 4242341 | 4242751 | 530329 | 5303873
Assignee Applicant: Dana-Farber Cancer Institute Inc.,Boston
Title: PREVENTION OF TYPE 1 DIABETES BY TREG VACCINATION WITH AN INSULIN MIMETOPE
Usefulness: PREVENTION OF TYPE 1 DIABETES BY TREG VACCINATION WITH AN INSULIN MIMETOPE
Summary: The method is useful for increasing Treg cells specific for an antigen in a subject who is a candidate for a transplant (where the antigen is present in the transplant but not in the subject) and who does not have detectable cytotoxic T cells specific for the antigen, to treat transplant rejection and autoimmune diseases including multiple sclerosis, autoimmune myocarditis, pemphigus, celiac disease, myasthenia gravis, Hashimoto's thyroiditis, Graves disease, Addison's disease, chronic Lyme arthritis, Goodpasture's syndrome, Kawasaki disease, scleroderma, Sjogren's syndrome (all claimed), immunoglobulin E-mediated allergy, allergic symptoms or type I diabetes. No biological data given.
Novelty: Increasing regulatory T cells specific for an antigen in subject, useful to treat e.g. transplant rejection, Kawasaki disease and autoimmune myocarditis, comprises administering a mimotope of the antigen under sub-immunogenic conditions

Industry

Disease Diagnostic/Treatment

Sub Category

Other Disease

*Abstract

The DFCI scientists developed strategy to use specifically modified insulin mimetopes that are stronger agonists than natural ligand to efficiently induce Tregs and prevent diabetes development in NOD mouse model of the disease.

Country/Region

USA